slides · global inventory
Roadmap
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 3,235
Current window 1,831-1,860
Pages 108
Rows per page 30
Slide type
1,831-1,860 of 3,235
47
The slide uses a growth curve to illustrate technological progression over time.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
05
The slide uses a pipeline table format to show the progression of various drug candidates (SPY001-SPY230) across discovery, IND-enabling, and clinical stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
13
The slide uses a Gantt-style visualization to show the progress of various drug candidates (SPY001-SPY230).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
14
The slide uses a Gantt-style visualization to show the status of various drug development programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
30
The slide uses a table-like layout to represent a drug development pipeline.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
38
The slide uses a matrix-like layout to map targets and programs against development stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
42
The slide uses a timeline-based process diagram to illustrate the clinical trial strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
48
The slide uses a table-based timeline structure to map specific drug candidates (SPY001-004) to expected regulatory and clinical milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
06
The slide uses a split-screen layout to contrast established proof-of-concept (left) with future development plans (right).argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · RoadmapLoop · Maturity Curve1 hit
09
The slide uses a 3D-like coordinate system to represent growth vectors.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Roadmap1 hit
03
The slide uses a Gantt-style chart to map product development stages from pre-clinical to FDA approval.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
25
Focuses on regulatory strategy and clinical trial design parameters for Phase 3.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
23
The chart is a waterfall-style buildup of capacity (GWh) for Giga America.Freyr | Investor Day Presentation Deck | 29 slides · FREYR
Conference presentation Investor relations Beat · Satisfaction1 hit
07
The slide uses a Gantt-style chart to show the progression of various drug programs (IRAK4, IRAKIMiD, STAT3, MDM2, etc.) through discovery, IND enabling, and clinical phases.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
57
The slide title mentions KT-333, but the content refers to KT-253 throughout; this is likely a typo in the source deck.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
56
The slide uses a chevron-based timeline structure to categorize strategic priorities.Main Street Capital | Investor Day Presentation Deck | 155 slides · Main Street Capital Corporation
Conference presentation Investor relations 1 hit
17
Includes a mention of future feasibility projects like PancAlert and Crohn's disease tests.Mainz Biomed NV | Investor Presentation Deck | 25 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
18
The slide outlines R&D progress and strategic collaborations for a new diagnostic product.Mainz Biomed NV | Investor Presentation Deck | 25 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
50
The slide uses a Gantt-style chart to show the progress of various drug candidates through clinical development stages.MindMed | Investor Day Presentation Deck | 61 slides · MindMed
Conference presentation Investor relations Loop · Mece Breakdown1 hit
59
The slide uses a process-oriented layout to define the commercialization strategy.MindMed | Investor Day Presentation Deck | 61 slides · MindMed
Conference presentation Investor relations 1 hit
08
The slide uses a Gantt-style chart to show the progress of different drug candidates through clinical development stages.MindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
MindMed | Investor Presentation Deck | 36 slidesMindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The slide uses a timeline diagram to illustrate the study flow from randomization to follow-up.MindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations 1 hit
18
The slide uses a process-oriented layout to describe the commercialization strategy.MindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations 1 hit
19
MindMed | Investor Presentation Deck | 36 slidesMindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations Loop · Why Now1 hit
34
The slide uses a matrix-like layout to show product status across development phases.MindMed | Investor Presentation Deck | 36 slides · MindMed
Pitch deck Investor relations Beat · Financials1 hit
03
The slide uses a standard drug development pipeline visualization.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
19
Includes a progress bar at the bottom indicating the current stage is Phase 2b.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
04
The chart uses a horizontal bar format to represent clinical trial progression stages.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
34
The slide uses a 2x3 grid layout to present strategic priorities.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations 1 hit